In 2013, The WHO’s African Programme for Onchocerciasis Control (APOC) reviewed its long-term goals in light of the NTD sector’s shift toward addressing NTDs in an integrated fashion. The result of this review led to a decision to transition APOC from solely focusing on treatment of river blindness to expanding their mission to target treatment for LF. APOC reached out to the END Fund in early 2014 regarding a funding gap in their Cote D’Ivoire program that targeted a total of 10 million people for treatment of LF.
END Fund Investment
The END Fund is partnering with APOC to support a one- year expanded program in Cote D’Ivoire to include treatment for LF.
Program to Date
This program launched in 2014 and aims to provide treatment for 10,000,000 individuals. The END Fund will support treatment in 55 at-risk districts in Cote D’Ivoire through the APOC model of community-directed treatment with ivermectin (CDTI). In preparation for the treatment campaign, 12,000 community drugs distributors and health workers will be trained.